Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Boston Medical Center and Boston University School of Medicine, Boston, MA.
J Addict Med. 2010 Sep;4(3):123-30. doi: 10.1097/ADM.0b013e3181db6b67.
The efficacy of screening and brief intervention (SBI) for drug use in primary care patients is largely unknown. Because of this lack of evidence, US professional organizations do not recommend it. Yet, a strong theoretical case can be made for drug SBI. Drug use is common and associated with numerous health consequences, patients usually do not seek help for drug abuse and dependence, and SBI has proven efficacy for unhealthy alcohol use. On the other hand, the diversity of drugs of abuse and the high prevalence of abuse and dependence among those who use them raise concerns that drug SBI may have limited or no efficacy. Federal efforts to disseminate SBI for drug use are underway, and reimbursement codes to compensate clinicians for these activities have been developed. However, the discrepancies between science and policy developments underscore the need for evidence-based research regarding the efficacy of SBI for drug use. This article discusses the rationale for drug SBI and existing research on its potential to improve drug-use outcomes and makes the argument that randomized controlled trials to determine its efficacy are urgently needed to bridge the gap between research, policy, and clinical practice.
在初级保健患者中进行药物使用筛查和简短干预(SBI)的效果在很大程度上尚不清楚。由于缺乏证据,美国专业组织不建议这样做。然而,药物 SBI 有强有力的理论依据。药物使用很常见,并且与许多健康后果相关,患者通常不会寻求药物滥用和依赖的帮助,并且 SBI 已被证明对不健康的饮酒行为有效。另一方面,滥用药物的多样性以及滥用和依赖药物的人患病率很高,这让人担心药物 SBI 的效果可能有限或无效。美国联邦政府正在努力推广药物使用 SBI,并且已经开发出了用于补偿临床医生开展这些活动的报销代码。然而,科学和政策发展之间的差异突显了需要开展基于证据的研究,以确定 SBI 对药物使用的疗效。本文讨论了药物 SBI 的基本原理,以及现有研究表明其改善药物使用结果的潜力,并提出了这样的论点,即迫切需要进行随机对照试验来确定其疗效,以缩小研究、政策和临床实践之间的差距。